経口補水液（ORS）の世界市場2022-2031：産業分析、規模、シェア、成長、動向、予測

• 英文タイトル：Oral Rehydration Solution [ORS] Market (Product Sales: OTC Products and Prescription Products; and Dosage Form: Powder, Liquid, and Tablet) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

• レポートコード：MRC2301F0080 • 出版社/出版日：Transparency Market Research / 2022年10月19日 • レポート形態：英文、PDF、211ページ • 納品方法：Eメール • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥857,660 (USD5,795)	▷ お問い合わせ
Multi User	￥1,301,660 (USD8,795)	▷ お問い合わせ
Corporate License	￥1,745,660 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

トランスペアレンシー・マーケット・リサーチ社の当調査資料では、世界の経口補水液（ORS）市場について総合的に調査・分析を行い、序論、仮定・調査手法、市場概要、主要インサイト、物販別（OTC製品、処方箋）分析、剤形別（粉末、液体、錠剤）分析、年齢別（子供、大人）分析、疾患別（下痢、胃腸炎、電解質異常、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況、企業情報などの項目を掲載しています。なお、当市場の主要企業には、FDC Limited、Cipla、Wallace Pharmaceuticals、Zydus Cadila Healthcare Ltd.、Shereya Life Sciences、Mankind Pharma、Intas Pharmaceuticals Ltd.、Sun Pharma、Dr Reddy's、Alkemなどが含まれています。 ・序論 ・仮定・調査手法 ・市場概要 ・主要インサイト ・世界の経口補水液（ORS）市場規模：物販別 - OTC製品の市場規模 - 処方箋の市場規模 ・世界の経口補水液（ORS）市場規模：剤形別 - 粉末経口補水液の市場規模 - 液体経口補水液の市場規模 - 錠剤経口補水液の市場規模 ・世界の経口補水液（ORS）市場規模：年齢別 - 子供における市場規模 - 大人における市場規模 ・世界の経口補水液（ORS）市場規模：疾患別 - 下痢における市場規模 - 胃腸炎における市場規模 - 電解質異常における市場規模 - その他疾患における市場規模 ・世界の経口補水液（ORS）市場規模：地域別 - 北米の経口補水液（ORS）市場規模 - ヨーロッパの経口補水液（ORS）市場規模 - アジア太平洋の経口補水液（ORS）市場規模 - 中南米の経口補水液（ORS）市場規模 - 中東/アフリカの経口補水液（ORS）市場規模 ・競争状況 ・企業情報

Oral Rehydration Solution (ORS) Market – Scope of Report
TMR’s report on the global oral rehydration solution (ORS) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global oral rehydration solution (ORS) market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oral rehydration solution (ORS) market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the oral rehydration solution (ORS) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oral rehydration solution (ORS) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global oral rehydration solution (ORS) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oral rehydration solution (ORS) market.

The report delves into the competitive landscape of the global oral rehydration solution (ORS) market. Key players operating in the global oral rehydration solution (ORS) market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global oral rehydration solution (ORS) market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market oral rehydration solution (ORS).

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

レポート目次

---

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oral Rehydration Solution (ORS) Market
4. Market Overview
4.1. Introduction
4.1.1. Product Sales Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, 2017–2031
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Raw material and Pricing trends
5.2. Regulatory Scenario by Region/globally
5.3. COVID-19 Impact Analysis
5.4. ORS campaigns by global institutions/NGOs
6. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Product Sales
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Sales, 2017–2031
6.3.1. OTC Products
6.3.2. Prescription
6.4. Market Attractiveness Analysis, By Product Sales
7. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Dosage Form
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Dosage Form, 2017–2031
7.3.1. Powder
7.3.2. Liquid
7.3.3. Tablet
7.4. Market Attractiveness Analysis, By Dosage Form
8. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Customer Age
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Customer Age, 2017–2031
8.3.1. Children
8.3.2. Adult
8.4. Market Attractiveness Analysis, By Customer Age
9. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Indication, 2017–2031
9.3.1. Diarrhea
9.3.2. Gastroenteritis
9.3.3. Electrolyte Imbalance
9.3.4. Others
9.4. Market Attractiveness Analysis, By Indication
10. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis, By Distribution Channel
11. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, By Region
12. North America Oral Rehydration Solution (ORS) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Sales, 2017–2031
12.2.1. OTC Products
12.2.2. Prescription
12.3. Market Value Forecast, by Dosage Form, 2017–2031
12.3.1. Powder
12.3.2. Liquid
12.3.3. Tablet
12.4. Market Value Forecast, by Customer Age, 2017–2031
12.4.1. Children
12.4.2. Adult
12.5. Market Value Forecast, by Indication, 2017–2031
12.5.1. Diarrhea
12.5.2. Gastroenteritis
12.5.3. Electrolyte Imbalance
12.5.4. Others
12.6. Market Value Forecast, by Distribution Channel, 2017–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Product Sales
12.8.2. By Dosage Form
12.8.3. By Customer Age
12.8.4. By Indication
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Oral Rehydration Solution (ORS) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Sales, 2017–2031
13.2.1. OTC Products
13.2.2. Prescription
13.3. Market Value Forecast, by Dosage Form, 2017–2031
13.3.1. Powder
13.3.2. Liquid
13.3.3. Tablet
13.4. Market Value Forecast, by Customer Age, 2017–2031
13.4.1. Children
13.4.2. Adult
13.5. Market Value Forecast, by Indication, 2017–2031
13.5.1. Diarrhea
13.5.2. Gastroenteritis
13.5.3. Electrolyte Imbalance
13.5.4. Others
13.6. Market Value Forecast, by Distribution Channel, 2017–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Product Sales
13.8.2. By Dosage Form
13.8.3. By Customer Age
13.8.4. By Indication
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Oral Rehydration Solution (ORS) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Sales, 2017–2031
14.2.1. OTC Products
14.2.2. Prescription
14.3. Market Value Forecast, by Dosage Form, 2017–2031
14.3.1. Powder
14.3.2. Liquid
14.3.3. Tablet
14.4. Market Value Forecast, by Customer Age, 2017–2031
14.4.1. Children
14.4.2. Adult
14.5. Market Value Forecast, by Indication, 2017–2031
14.5.1. Diarrhea
14.5.2. Gastroenteritis
14.5.3. Electrolyte Imbalance
14.5.4. Others
14.6. Market Value Forecast, by Distribution Channel, 2017–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Product Sales
14.8.2. By Dosage Form
14.8.3. By Customer Age
14.8.4. By Indication
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Oral Rehydration Solution (ORS) Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Sales, 2017–2031
15.2.1. OTC Products
15.2.2. Prescription
15.3. Market Value Forecast, by Dosage Form, 2017–2031
15.3.1. Powder
15.3.2. Liquid
15.3.3. Tablet
15.4. Market Value Forecast, by Customer Age, 2017–2031
15.4.1. Children
15.4.2. Adult
15.5. Market Value Forecast, by Indication, 2017–2031
15.5.1. Diarrhea
15.5.2. Gastroenteritis
15.5.3. Electrolyte Imbalance
15.5.4. Others
15.6. Market Value Forecast, by Distribution Channel, 2017–2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Product Sales
15.8.2. By Dosage Form
15.8.3. By Customer Age
15.8.4. By Indication
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Oral Rehydration Solution (ORS) Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Product Sales, 2017–2031
16.2.1. OTC Products
16.2.2. Prescription
16.3. Market Value Forecast, by Dosage Form, 2017–2031
16.3.1. Powder
16.3.2. Liquid
16.3.3. Tablet
16.4. Market Value Forecast, by Customer Age, 2017–2031
16.4.1. Children
16.4.2. Adult
16.5. Market Value Forecast, by Indication, 2017–2031
16.5.1. Diarrhea
16.5.2. Gastroenteritis
16.5.3. Electrolyte Imbalance
16.5.4. Others
16.6. Market Value Forecast, by Distribution Channel, 2017–2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Product Sales
16.8.2. By Dosage Form
16.8.3. By Customer Age
16.8.4. By Indication
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis, by Company, 2021
17.3. Company Profiles
17.3.1. FDC Limited
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. SWOT Analysis
17.3.1.4. Strategic Overview
17.3.2. Cipla
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. SWOT Analysis
17.3.2.4. Strategic Overview
17.3.3. Wallace Pharmaceuticals
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. SWOT Analysis
17.3.3.4. Strategic Overview
17.3.4. Zydus Cadila Healthcare Ltd.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. SWOT Analysis
17.3.4.4. Strategic Overview
17.3.5. Shereya Life Sciences
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. SWOT Analysis
17.3.5.4. Strategic Overview
17.3.6. Mankind Pharma
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. SWOT Analysis
17.3.6.4. Strategic Overview
17.3.7. Intas Pharmaceuticals Ltd.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. SWOT Analysis
17.3.7.4. Strategic Overview
17.3.8. Sun Pharma
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. SWOT Analysis
17.3.8.4. Strategic Overview
17.3.9. Dr Reddy’s
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. SWOT Analysis
17.3.9.4. Strategic Overview
17.3.10. Alkem
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. SWOT Analysis
17.3.10.4. Strategic Overview
17.3.11. Lupin
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Product Portfolio
17.3.11.3. SWOT Analysis
17.3.11.4. Strategic Overview
17.3.12. Cadila
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Product Portfolio
17.3.12.3. SWOT Analysis
17.3.12.4. Strategic Overview
17.3.13. RPG Life Sciences
17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.13.2. Product Portfolio
17.3.13.3. SWOT Analysis
17.3.13.4. Strategic Overview
17.3.14. Casca remedies Pvt. Ltd.
17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.14.2. Product Portfolio
17.3.14.3. SWOT Analysis
17.3.14.4. Strategic Overview
17.3.15. Halewood Laboratories Pvt. Ltd.
17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.15.2. Product Portfolio
17.3.15.3. SWOT Analysis
17.3.15.4. Strategic Overview
17.3.16. Liquid I.V.
17.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.16.2. Product Portfolio
17.3.16.3. SWOT Analysis
17.3.16.4. Strategic Overview

---